European Radiology:究竟哪些肝炎患者需要做EOB-MRI检查?这个血清学指标你一定要知道!

2022-05-01 shaosai MedSci原创

非血管性低信号结节(NHHNs)是通过普美显增强磁共振成像(EOB-MRI)检测出的一类肝脏结节。

肝细胞癌(HCC)是目前世界上最常见的癌症相关死亡原因之一,其中HCV感染是HCC的一个主要原因。HCC患者的预后在很大程度上取决于早期发现和治疗。对高危患者进行HCC监测与早期发现、进行根治性治疗和更好的总生存率相关。因此,有效的HCC监测和识别有HCC风险的患者对于改善预后非常重要。

血管性低信号结节(NHHNs)是通过普美显增强磁共振成像(EOB-MRI)检测一类肝脏结节。在肝胆期,NHHNs相对于肝实质显示为较低信号,但在动脉期呈弱强化。以前的研究报告指出,NHHNs在长期随访过程中,随着其体积的增长很有可能出现血管增粗的现象。血管过多的结节通常具有HCC的影像学特征,包括廓清包膜强化常提示发展为典型HCC。因此,NHHN的存在是HCC发展的一个强有力的风险因素。因此,HCC的高风险患者可以通过NHHN的存在来识别。

据报道,FIB-4指数值与HCV感染患者的HCC发展有关。血清甲胎蛋白(AFP)是HCC的一个肿瘤标志物。最近的一项研究报告说,HCC患者的AFP水平在确诊HCC前很久就已经升高。另一项研究报告说,血清中WFA+-M2BP的升高与HCV感染患者HCC的高发生率有关。

近日,发表在European Radiology杂志的一项研究评估了HCC潜在的基于实验室的风险因素与HCV感染患者中NHHNs的存在之间的关系,这可协助临床识别出有高风险NHHNs存在的患者以进行进一步的EOB-MRI检查以明确诊断

本研究对481名接受EOB-MRI检查的HCV感染和无HCC病史的患者测量了三种血清标志物,即甲胎蛋白(AFP)、FIB-4指数和M2BPGi,研究了这些血清标志物水平与NHHNs的存在之间的关联。 

所有三个标志物都与NHHNs的存在有关。M2BPGi比AFP和FBB-4指数更准确地预测NHHNs的存在;M2BPGi的ROC曲线下面积最高。多变量分析确定男性和高M2BPGi是与NHHNs存在相关的因素。当患者按肝脏纤维化程度分层时,M2BPGi随着纤维化的进展而增加。此外,在纤维化程度相似的患者中,M2BPGi较高(COI>3.46)的患者更容易发现NHHNs。 


 EOB-MRI图像上的非血管性低信号结节(NHHNs)向血管性肝癌(HCC)的转变。上图为EOB-MRI的早期动脉期;下图为EOB-MRI的肝胆期。(a)NHHN和(b)NHHN的高血管化

本研究显示,在慢性HCV感染患者中,NHHNs的存在与M2BPGi、AFP和FIB-4指数值之间存在相关性。特别是,M2BPGi与NHHNs的存在独立相关,是确定EOB-MRI合适人选的一个潜在血清学指标。

原文出处:

Hidenori Toyoda,Satoshi Yasuda,Shohei Shiota,et al.Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.DOI:10.1007/s00330-022-08570-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1729525, encodeId=79bc1e29525d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 13 03:49:17 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807930, encodeId=d65b180e930ad, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Dec 30 13:49:17 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316058, encodeId=a7751316058ec, content=<a href='/topic/show?id=37cb1221405' target=_blank style='color:#2F92EE;'>#MRI检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12214, encryptionId=37cb1221405, topicName=MRI检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468994, encodeId=686014689945a, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
    2022-11-13 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1729525, encodeId=79bc1e29525d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 13 03:49:17 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807930, encodeId=d65b180e930ad, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Dec 30 13:49:17 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316058, encodeId=a7751316058ec, content=<a href='/topic/show?id=37cb1221405' target=_blank style='color:#2F92EE;'>#MRI检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12214, encryptionId=37cb1221405, topicName=MRI检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468994, encodeId=686014689945a, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1729525, encodeId=79bc1e29525d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 13 03:49:17 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807930, encodeId=d65b180e930ad, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Dec 30 13:49:17 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316058, encodeId=a7751316058ec, content=<a href='/topic/show?id=37cb1221405' target=_blank style='color:#2F92EE;'>#MRI检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12214, encryptionId=37cb1221405, topicName=MRI检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468994, encodeId=686014689945a, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1729525, encodeId=79bc1e29525d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 13 03:49:17 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807930, encodeId=d65b180e930ad, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Dec 30 13:49:17 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316058, encodeId=a7751316058ec, content=<a href='/topic/show?id=37cb1221405' target=_blank style='color:#2F92EE;'>#MRI检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12214, encryptionId=37cb1221405, topicName=MRI检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468994, encodeId=686014689945a, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Tue May 03 04:49:17 CST 2022, time=2022-05-03, status=1, ipAttribution=)]

相关资讯

AP&T: 慢性病毒性肝炎并发脂肪肝的肝细胞癌风险和死亡率会明显增加

肝细胞癌(HCC)是肝癌的主要组织学亚型,占原发性肝癌的90%,是全世界癌症相关死亡率的第三大常见原因。

European Radiology:Gd-EOB-DTPA增强MRI,实现HCC微血管浸润的无创评估!

微血管侵犯(MVI)是肝细胞癌(HCC)复发和影响预后的一个重要风险因素。对于有MVI的HCC患者,应扩大手术切除和射频消融的边缘范围,同时也应考虑将肝移植纳入替代治疗方法之一。

European Radiology:MRE在评估HCC微血管侵犯中的应用

MR弹性成像(MRE)是一项成熟的技术,在检测和分期肝脏纤维化方面具有很高的诊断性能,同时在评估恶性肿瘤方面也有新的作用。

European Radiology:对于不同机构、不同机器、不同场强下进行的钆塞酸二钠增强MRI,是否仍可反应肝脏增强与肝功能的相关性?

钆塞酸二钠是一种肝细胞特异性对比剂,显示出选择性的肝细胞摄取,并在注射后约20分钟达到峰值(肝胆期)。

European Radiology:深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值

肝细胞肝癌(HCC)的根治性切除术是早期HCC患者的第一选择。然而,术后2年的复发率很高,达到50%。

European Radiology:因为这一征象,我们改良了LI-RADS!

肝脏成像报告和数据系统(LI-RADS)是一个综合评估系统,主要目的是规范成像结果的词汇、解释和报告,以提高影像科内部与各科室之间高危肝细胞癌(HCC)诊断相关的解析及交流。